BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26215196)

  • 1. The Importance of Applying ACOSOG Z0011 Criteria in the Axillary Management of Invasive Lobular Carcinoma: A Multi-institutional Cohort Study.
    Roberts A; Nofech-Mozes S; Youngson B; McCready DR; Al-Assi M; Ramkumar S; Cil T
    Ann Surg Oncol; 2015 Oct; 22(10):3397-401. PubMed ID: 26215196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers.
    Mamtani A; Zabor EC; Stempel M; Morrow M
    Ann Surg Oncol; 2019 Oct; 26(10):3269-3274. PubMed ID: 31342363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis.
    Caretta-Weyer H; Greenberg CG; Wilke LG; Weiss J; LoConte NK; Decker M; Steffens NM; Smith MA; Neuman HB
    Ann Surg Oncol; 2013 Dec; 20(13):4145-52. PubMed ID: 23959051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
    Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
    Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?
    Pilewskie M; Mautner SK; Stempel M; Eaton A; Morrow M
    Ann Surg Oncol; 2016 Apr; 23(4):1123-8. PubMed ID: 26553439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
    Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
    Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns.
    Caudle AS; Hunt KK; Tucker SL; Hoffman K; Gainer SM; Lucci A; Kuerer HM; Meric-Bernstam F; Shah R; Babiera GV; Sahin AA; Mittendorf EA
    Ann Surg Oncol; 2012 Oct; 19(10):3144-51. PubMed ID: 22847123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
    Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
    Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.
    Morrow M; Van Zee KJ; Patil S; Petruolo O; Mamtani A; Barrio AV; Capko D; El-Tamer M; Gemignani ML; Heerdt AS; Kirstein L; Pilewskie M; Plitas G; Sacchini VS; Sclafani LM; Ho A; Cody HS
    Ann Surg; 2017 Sep; 266(3):457-462. PubMed ID: 28650355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.
    Shah-Khan M; Boughey JC
    Cancer Control; 2012 Oct; 19(4):267-76. PubMed ID: 23037494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients.
    van den Hoven I; van Klaveren D; Voogd AC; Vergouwe Y; Tjan-Heijnen V; Roumen RM
    Clin Breast Cancer; 2016 Apr; 16(2):123-30. PubMed ID: 26602438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do the ACOSOG Z0011 Criteria Affect the Number of Sentinel Lymph Nodes Removed?
    Subhedar P; Stempel M; Eaton A; Morrow M; Gemignani ML
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(0 3):S470-5. PubMed ID: 26178759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
    Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
    Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery.
    Kittaka N; Tokui R; Ota C; Hashimoto Y; Motomura K; Ishitobi M; Nakayama T; Tamaki Y
    Int J Clin Oncol; 2018 Oct; 23(5):860-866. PubMed ID: 29789974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
    Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
    Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast-Enhanced Ultrasound Biopsy of Sentinel Lymph Nodes in Patients with Breast Cancer: Implications for Axillary Metastases and Conservation.
    Cox K; Weeks J; Mills P; Chalmers R; Devalia H; Fish D; Sever A
    Ann Surg Oncol; 2016 Jan; 23(1):58-64. PubMed ID: 25990967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is SLN Biopsy Alone Safe in SLN Positive Breast Cancer Patients?
    van la Parra RF; de Wilt JH; Mol SJ; Mulder AH; de Roos WK; Bosscha K
    Breast J; 2015; 21(6):621-6. PubMed ID: 26391102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
    Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
    Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.